Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Alkermes Plc

Alkermes Plc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)29.36
  • Today's Change0.58 / 2.02%
  • Shares traded2.03m
  • 1 Year change+20.38%
  • Beta0.4477
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

  • Revenue in USD (TTM)1.51bn
  • Net income in USD502.58m
  • Incorporated2011
  • Employees2.10k
  • Location
    Alkermes PlcConnaught House1 Burlington Road, Dublin 4DUBLIN D04 C5Y6IrelandIRL
  • Phone+353 17728000
  • Websitehttps://www.alkermes.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MoonLake Immunotherapeutics0.00-80.77m3.47bn50.00--7.01-----1.29-1.290.007.740.00----0.00-16.25---18.06--------------0.00------27.95------
Immunitybio Inc7.33m-587.79m3.55bn672.00------484.50-0.867-0.8670.0108-1.070.0184--1.5311,675.16-147.53-112.76-182.67-316.07-----8,018.00-37,700.742.64-2.194.22--159.1767.62-40.00--18.48--
Denali Therapeutics Inc0.00-427.49m3.55bn390.00--2.69-----2.76-2.760.009.170.00----0.00-31.77-14.98-33.76-17.71-------104.50----0.0043--204.7420.6755.45--30.70--
Alvotech SA393.92m-441.45m3.61bn999.00------9.18-1.90-1.901.56-1.290.35951.564.24394,313.30-40.28---47.87--59.03---112.07--1.92-0.05191.41--9.84---7.43------
Rhythm Pharmaceuticals Inc112.53m-261.57m3.68bn226.00--328.35--32.74-4.31-4.311.862.490.31361.186.65497,920.30-72.15-47.21-90.85-52.8488.61---230.11-681.383.34--0.417--227.56---1.97---42.10--
Immunovant Inc0.00-323.01m3.94bn207.00--8.77-----2.21-2.210.003.060.00----0.00-79.97---92.17--------------0.00-------22.93------
Ultragenyx Pharmaceutical Inc522.75m-558.99m4.36bn1.28k--12.57--8.35-6.46-6.466.023.760.37661.916.06409,674.80-40.27-33.35-50.12-38.3086.2593.13-106.93-154.712.65--0.00--19.5253.1814.25--62.91--
Biohaven Ltd0.00-804.34m4.49bn239.00--13.69-----9.35-9.350.003.330.00----0.00-180.09---236.99--------------0.00------28.43------
Alkermes Plc1.51bn502.58m4.66bn2.10k9.753.608.583.092.951.968.837.990.67881.324.24716,724.3022.671.3428.901.7483.1783.3233.392.123.03--0.18270.0049.618.741,665.99---7.10--
Arcellx Inc155.82m-40.42m4.89bn130.00--10.11--31.39-0.7196-0.71962.988.950.226----1,198,600.00-5.86-38.82-7.56-45.41-----25.94-339.38----0.022------62.53--113.86--
Crinetics Pharmaceuticals Inc1.04m-277.91m5.01bn290.00--5.44--4,819.47-3.72-3.720.013910.300.0013--0.12223,582.76-34.61-42.53-36.80-45.36-----26,298.27-5,446.39----0.00---15.2810.57-30.88--34.65--
Ionis Pharmaceuticals Inc803.07m-358.81m5.37bn927.00--8.10--6.69-2.45-2.455.504.200.2670.386410.02866,306.40-11.93-6.30-13.52-7.4498.7098.75-44.68-21.238.82--0.6587--34.105.60-35.80--11.83--
TG Therapeutics Inc264.79m-14.36m5.46bn319.00--28.43--20.62-0.1067-0.10671.741.230.57750.52343.421,002,992.00-3.13-62.87-3.91-80.0688.32---5.42-405.033.910.20970.5596--8,290.02333.86106.39------
Krystal Biotech Inc241.52m52.37m5.48bn229.00107.736.1892.1722.671.771.778.2130.800.27251.514.531,054,664.005.91-11.506.33-12.0192.55--21.68-492.857.76--0.00------107.81--39.49--
Cytokinetics, Inc.3.22m-576.40m5.79bn423.00------1,800.09-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Data as of Nov 25 2024. Currency figures normalised to Alkermes Plc's reporting currency: US Dollar USD

Institutional shareholders

63.07%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 202424.80m15.32%
The Vanguard Group, Inc.as of 30 Sep 202418.46m11.41%
T. Rowe Price Associates, Inc. (IM)as of 30 Sep 202412.78m7.90%
Wellington Management Co. LLPas of 30 Sep 202412.54m7.75%
SSgA Funds Management, Inc.as of 30 Sep 20249.19m5.68%
RTW Investments LPas of 30 Sep 20246.65m4.11%
Renaissance Technologies LLCas of 30 Sep 20245.42m3.35%
Baker Bros. Advisors LPas of 30 Sep 20244.18m2.58%
Pacer Advisors, Inc.as of 30 Sep 20244.17m2.57%
Geode Capital Management LLCas of 30 Sep 20243.87m2.39%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.